4:01 PM
 | 
Dec 05, 2017
 |  BC Extra  |  Company News

FDA reviewing Rubraca for ovarian cancer maintenance

FDA accepted and granted Priority Review to an sNDA from Clovis Oncology Inc. (NASDAQ:CLVS) for Rubraca rucaparib as maintenance therapy for women with recurrent, platinum-sensitive ovarian cancer, regardless...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >